Anti-CD25 Humanized monoclonal antibody used for immunosuppression in organ Transplant patient is:

Basiliximab is an Anti-CD25 Antibody (IL-2 receptor antagonists used for immunosuppression in organ transplant patiennts. Monoclonal Antibodies as Immunosuppressive agents in Organ Transplantation: Anti-CD3- Muromonab-CD3 Anti-CD20-Rituximab Anti-CD25 (IL 2 receptor)- Basiliximab(Chimeric), Daclizumab(Humanized) Anti-CD52-Alemtuzumab Drug (Trade name) Target Monoclonal Antibody Type Mechanism Muromonab-CD3 (Ohoclone OKT3) Anti-CD3 Murine(Mouse) Monoclonal antibody Binds CD3 associated with the TCR, leading to initial activation and cytokine release, followed by blockade of function, lysis and T cell depletion Rituximab (Rituxan) Anti-CD20 Recombinant Chimeric Monoclonal antibody Binds to CD20 on B cells and causes depletion Basiliximab (Simulect) Anti-CD25 Recombinant Chimeric Monoclonal Antibody Binds to high-affinity chain of IL-2 Receptors (CD25) on activated T cells, causing depletion and preventing IL-2 mediated activation Daclizumab (Zenopax) Anti-CD25 Recombinant Humanized Monoclonal Antibody Similar to that of Basiliximab Alemtuzumab (Campath-1h) Anti-CD52 Recombinant Humanized Monoclonal Antibody Binds to CD52 expressed on most T and B cells, monocytes, macrophages, and NK cells, causing lysis and prolonged depletion Ref: KDT 7th edition Pgno: 878